4,582 Shares in Biogen Inc. $BIIB Purchased by EFG International AG

EFG International AG acquired a new position in shares of Biogen Inc. (NASDAQ:BIIB) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 4,582 shares of the biotechnology company’s stock, valued at approximately $990,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Reflection Asset Management acquired a new stake in shares of Biogen during the fourth quarter worth approximately $25,000. Bell Investment Advisors Inc acquired a new position in Biogen in the 2nd quarter valued at approximately $27,000. WFA of San Diego LLC acquired a new position in Biogen in the 2nd quarter valued at approximately $32,000. Root Financial Partners LLC lifted its position in Biogen by 198.4% in the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock worth $33,000 after buying an additional 123 shares in the last quarter. Finally, MV Capital Management Inc. purchased a new stake in Biogen in the 4th quarter worth approximately $34,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Analyst Ratings Changes

BIIB has been the topic of several research analyst reports. Wedbush boosted their price target on shares of Biogen from $201.00 to $215.00 and gave the company a “neutral” rating in a report on Thursday, July 30th. Truist Financial upgraded Biogen from a “hold” rating to a “buy” rating and increased their price objective for the stock from $190.00 to $235.00 in a report on Monday, July 13th. HC Wainwright lifted their price objective on Biogen from $237.00 to $251.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Wolfe Research upgraded Biogen from a “peer perform” rating to an “outperform” rating and set a $300.00 target price on the stock in a research note on Thursday, August 13th. Finally, HSBC reaffirmed a “reduce” rating and issued a $157.00 target price on shares of Biogen in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Biogen presently has an average rating of “Moderate Buy” and an average target price of $227.79.

Biogen Trading Up 0.1%

NASDAQ:BIIB opened at $221.07 on Thursday. The company’s 50 day moving average is $206.87 and its 200-day moving average is $195.38. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. Biogen Inc. has a 12 month low of $131.52 and a 12 month high of $222.85. The firm has a market cap of $32.66 billion, a price-to-earnings ratio of 39.13, a P/E/G ratio of 6.88 and a beta of 0.17.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The business had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. During the same period in the prior year, the firm earned $5.47 EPS. Biogen’s quarterly revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities analysts anticipate that Biogen Inc. will post 12.39 EPS for the current year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.